Positive Phase 2 Results for Tipifarnib in HRAS Mutant
Head and Neck Cancer

Four of the first six HRAS Mutant HNSCC Patients enrolled on study achieve confirmed RECIST Partial Responses and Durable Responses Greater than One Year  

On September 7, 2017, i.e., five days ago, Kura Oncology (KURA) announced positive results from a Phase 2 trial from its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory head and neck squamous . . .